In conclusion, we report the safety of CVP-NASVAC and demonstrate that CVP-NASVAC induces anti-HBs, anti-HBc, IgA-type anti-HBs, and HBV-specific CTL production in HB vaccine non-responders. Here, CD79A is linked to hemoglobin measurement.